Navigation Links
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Date:10/27/2009

ica, Inc. ($27.2M). (4) To exclude costs related to the CIMA restructuring. (5) To exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. (6) To exclude non-cash interest expense associated with our convertible debt ($40.5M in 2009; $36.3M in 2008) and accrued interest related to the agreement in principle reached with the U.S. Attorney's Office in Philadelphia ($11.3M in 2008). (7) In 2009, to exclude the following gains and losses related to the acquisition of Arana Therapeutics Limited: - $6.6M gain on pre-bid Arana holdings; - $2.8M loss on contingent consideration (90% ownership incentive payment); - $10.0M gain on the excess of net assets over consideration; - $19.0M gains on foreign exchange derivative instruments; - $5.6M foreign exchange gain on Australian Dollar acquisition funds; and - $1.6M dividend income related to our initial purchase of Arana shares. (8) To exclude charges related to the deconsolidation of Acusphere ($9.3M), the acquisition of worldwide license rights related to LUPUZOR from ImmuPharma ($30.0M), license rights for bendamustine hydrochloride in China and Hong Kong ($0.8M) and license rights to certain of XOMA Ltd.'s proprietary antibody library materials ($6.0M) in 2009 and the license of Acusphere HDDS technology for use in oncology therapeutics in 2008. (9) In 2009 to exclude the portion of non-cash charges related to our acquisition of Arana Therapeutics Limited that are reflected in adjustments (7) above but do not affect net income because they are attributed to noncontrolling interests. (10) To reflect the tax effect of pre-tax adjustments at applicable tax rates and certain other tax adjustments primarily related to the tax benefits for the settlement
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... -- An analysis done by the CVS Health Research ... new and expensive treatment for Hepatitis C introduced in ... months (May through August 2014) there has been a ... suggests another surge of patients will begin therapy when ... and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Synteract, Inc ., a full-service contract ... training classes for CDISC , a global, ... the acquisition, exchange, submission and archive of clinical ... 21-24, 2012 at Synteract,s Carlsbad, Calif., headquarters. ...
... COLUMBUS, Ohio, Feb. 17, 2012  Chemical Abstracts Service ... Taylor & Francis, a leading publisher of scientific ... new experimental procedures for chemical reactions from three ... SciFinder®. (Logo: http://photos.prnewswire.com/prnh/20110418/MM84805 ) ...
Cached Medicine Technology:Synteract Hosting CDISC Classes on Regulatory Data Standards, Feb. 21-24, in California 2CAS and Taylor & Francis Collaborate to Improve Scientists' Access to Published Research 2
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) ... to consider: , 1. The appropriate ... 2. The potential for adverse cardiovascular outcomes ... litigation ongoing, an informally-organized litigation group subcommittee prepared a ... replacement therapy. Among others, ZKB attorney Michelle L. Kranz ...
(Date:9/17/2014)... BOSTON September 17, 2014 Why are Asian ... than Caucasian Americans, and prone to develop the disease ... may lie in the transition from traditional high-fiber, low-fat ... extra risks for those of Asian heritage, says George ... at Joslin Diabetes Center and the senior author of ...
(Date:9/17/2014)... New York, NY (PRWEB) September 17, 2014 ... morcellators ( http://www.drugbot.com/morcellator/ ) in laparoscopic hysterectomies and other ... LLP reports. According to figures posted on Change.org, at ... September 17th. * , According to a recent report ... one year ago by Dr. Hooman Noorchashm, after his ...
(Date:9/17/2014)... 17, 2014 Cadiz Laser Spa ... cosmetic procedures to clients throughout Central Texas. The ... is Collagen Induction Therapy. Using the revolutionary Rejuvapen ... to help clients correct a wide variety of ... month, and Cadiz Laser Spa is currently offering ...
Breaking Medicine News(10 mins):Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2
... Extended One Year -LEXINGTON, Mass., Jan. 26 ... Chain Systems has extended its contract to offer ... This continues a successful history between the two ... contract covers IL,s portfolio of critical care analyzers, ...
... Medimetriks Pharmaceuticals announced today that the ... Company (Nasdaq: PRGO ), a leading manufacturer ... Exclusive Authorized Distributor of generic versions of Medimetriks, branded ... Medimetriks to receive a percentage of Perrigo,s Net Sales ...
... Authentidate Holding Corp. (Nasdaq: ADAT ... Exchange and workflow management services, announced today that ... LLC and Parascript Management, Inc. (collectively "Parascript") that ... Merger it entered into with Authentidate. The merger ...
... company awardIRVINE, Calif., Jan. 26 ChromaDex Corporation, ... reference standards and contract research, announced today that ... and alternative health care magazine, selected the Company ... Award recipients for its achievement in setting stevia ...
... Jan. 26 Trintech Group Plc (Nasdaq: ... governance, transaction risk management, and compliance solutions, today announced ... will meet on January 27 in Mountain View, California ... to share common experiences, discuss the latest market trends ...
... Health System announced,that it has launched the International ... for robotic surgical teams from around the world.,The launch ... annual,meeting in San Francisco. , ... robotic-assisted,surgery since we began our program in 2002," says ...
Cached Medicine News:Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 2Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 3Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 2Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 3Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 2Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 3Health News:Saint Joseph's Launches International College of Robotic Surgery 2
... Nebulizer Disposable Prefilled 28%-100% FIO 2 1000ML ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... modified nebulizer setups to deliver CNT and ... your patient is critical? OMNI~MAX has everything ... Heliox rescue therapy. In severe obstructive disease, ... of care in hospitals across the nation. ...
Medicine Products: